A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Phase of Trial: Phase II/III
Latest Information Update: 11 Dec 2019
Price : $35 *
At a glance
- Drugs Uproleselan-sodium (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 06 Nov 2019 Trial design released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 06 Nov 2019 According to a GlycoMimetics media release, data will be presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition.
- 30 Apr 2019 Planned number of patients changed from 932 to 670.